Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Laurie J. Reichling"'
Autor:
Taebo Sim, Yi Gao, Carson C. Thoreen, David M. Sabatini, Jianming Zhang, Laurie J. Reichling, Jae Won Chang, Nathanael S. Gray, Qingsong Liu, Seong A. Kang
Publikováno v:
Journal of Biological Chemistry. 295:2886
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::261cf6e8d1b26837311220db1636e581
https://doi.org/10.1074/jbc.aac120.012837
https://doi.org/10.1074/jbc.aac120.012837
Publikováno v:
SLAS Discovery. 17:813-821
Non-adenosine triphosphate (ATP) competitive, allosteric inhibitors provide a promising avenue to develop highly selective small-molecule kinase inhibitors. Although this class of compounds is growing, detection of such inhibitors can be challenging
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baffe0cfd7378bf40fac0b7f3eac2794
https://doi.org/10.1177/1087057112439889
https://doi.org/10.1177/1087057112439889
Autor:
Yi Gao, Kurt W. Vogel, Hildegard C. Eliason, Connie S. Lebakken, Steven M. Riddle, Laurie J. Reichling, Bryan D. Marks, W. Jack Frazee, Upinder Singh
Publikováno v:
Journal of biomolecular screening. 14(8)
The expansion of kinase assay technologies over the past decade has mirrored the growing interest in kinases as drug targets. As a result, there is no shortage of convenient, fluorescence-based methods available to assay targets that span the kinome.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a1d2776d73b22a4e5c18679a16a4850
https://pubmed.ncbi.nlm.nih.gov/19564447
https://pubmed.ncbi.nlm.nih.gov/19564447
Autor:
Laurie J. Reichling, Steven M. Riddle
Publikováno v:
Biochemical and biophysical research communications. 384(2)
Mutations in leucine-rich repeat kinase 2 (LRRK2) are a frequent cause of late-onset autosomal dominant Parkinson's disease (PD). Some disease-associated mutations directly affect LRRK2 kinase activity and inhibition of LRRK2 is viewed as a potential
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03805bbc10a7bd04bcde7c366fbbf99b
https://pubmed.ncbi.nlm.nih.gov/19397894
https://pubmed.ncbi.nlm.nih.gov/19397894
Autor:
Laurie J. Reichling, Yi Gao, Seong A. Kang, Nathanael S. Gray, Taebo Sim, David M. Sabatini, Carson C. Thoreen, Jianming Zhang, Qingsong Liu, Jae Won Chang
The mammalian target of rapamycin (mTOR) kinase is the catalytic subunit of two functionally distinct complexes, mTORC1 and mTORC2, that coordinately promote cell growth, proliferation, and survival. Rapamycin is a potent allosteric mTORC1 inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db44db8b99ba315f3d4f519b5814f309
https://europepmc.org/articles/PMC2658096/
https://europepmc.org/articles/PMC2658096/
Autor:
Steven M. Riddle, Eugene L. Brown, Vasanti S. Anand, Richard Somberg, Kerry Kelleher, Pooja Pungaliya, Wayne Stochaj, Warren D. Hirst, Peter H. Reinhart, Steven P. Braithwaite, Weili Duan, Kerri Lipinski, Laurie J. Reichling
Publikováno v:
The FEBS journal. 276(2)
Mutations in leucine-rich repeat kinase 2 (LRRK2) comprise the leading cause of autosomal dominant Parkinson's disease, with age of onset and symptoms identical to those of idiopathic forms of the disorder. Several of these pathogenic mutations are t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df5050abbf28183f941c26ca55054721
https://pubmed.ncbi.nlm.nih.gov/19076219
https://pubmed.ncbi.nlm.nih.gov/19076219
Autor:
Rica Bruinsma, Kurt W. Vogel, Leisha M. Kopp, Steven M. Riddle, Matthew B. Robers, Kevin L. Vedvik, Connie S. Lebakken, Laurie J. Reichling
Publikováno v:
Journal of biomolecular screening. 13(3)
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase involved in nutrient sensing and cell growth and is a validated target for oncology and immunosuppression. Two modes of direct small-molecule inhibition of mTOR activity are known:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e497d7f5c0032d4658731a0bc62fb13b
https://pubmed.ncbi.nlm.nih.gov/18354135
https://pubmed.ncbi.nlm.nih.gov/18354135
Autor:
Laurie J. Reichling, Tina Hallis, Spencer B. Hermanson, Jason Ellefson, Coby B. Carlson, Kun Bi, Connie S. Lebakken, Steve Riddle
Publikováno v:
Cancer Research. 72:3881-3881
Receptor tyrosine kinases (RTKs) are important pharmacological targets in oncology. Current biochemical assays designed to assess compound efficacy utilize truncated forms of the kinase lacking the transmembrane or extracellular domains and fail to a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5a9cb15e1c2d1e38d05c830f89befdf
https://doi.org/10.1158/1538-7445.am2012-3881
https://doi.org/10.1158/1538-7445.am2012-3881
Publikováno v:
Molecular Cancer Therapeutics. 10:C95-C95
Kinase activity-based assays are cost-effective and widely used to drive early drug discovery and lead identification, however, they typically require purified, active kinase preparations be produced that are shown to phosphorylate a known substrate.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff6688e966fa984ca9b64db89107ce1d
https://doi.org/10.1158/1535-7163.targ-11-c95
https://doi.org/10.1158/1535-7163.targ-11-c95
Publikováno v:
Cancer Research. 70:3688-3688
Kinase activity-based assays are cost-effective and widely used to drive early drug discovery and lead identification, however, they typically require purified, active kinase preparations to be produced that are shown to phosphorylate a known substra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fbf2bdfeb8defcd4159e98a2db59c491
https://doi.org/10.1158/1538-7445.am10-3688
https://doi.org/10.1158/1538-7445.am10-3688